Hypoparathyroidism Global Market Report 2025

The hypoparathyroidism market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the rising number of thyroid surgeries, increased awareness of hypoparathyroidism, a rise in postoperative complications, growing demand for calcium and vitamin D supplements, and heightened focus on managing endocrine disorders.

The hypoparathyroidism market size is expected to see strong growth in the next few years. It will grow to $1.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth during the forecast period can be attributed to the increasing adoption of recombinant parathyroid hormone therapies, rising investment in hypoparathyroidism research, expansion of healthcare infrastructure, a growing geriatric population vulnerable to endocrine disorders, and enhanced awareness and early diagnosis efforts. Key trends in this period include advancements in parathyroid hormone therapies, improved diagnostic techniques for hypoparathyroidism, development of sustained-release calcium supplements, innovations in minimally invasive thyroid surgery, and progress in patient monitoring technologies.

The rising incidence of thyroid cancer is expected to drive the growth of the hypoparathyroidism market in the coming years. Thyroid cancer is a type of cancer characterized by abnormal cell growth in the thyroid gland, often resulting in a lump in the neck. The increase in thyroid cancer cases is attributed to advancements in diagnostic imaging technologies, which allow for earlier and more frequent detection of small, asymptomatic thyroid nodules. Thyroid cancer contributes to hypoparathyroidism by increasing the number of thyroid surgeries, which can unintentionally damage the parathyroid glands. This damage leads to calcium imbalances and chronic hormone deficiency, boosting the demand for long-term disease management solutions. For example, in May 2024, the American Cancer Society, a US-based non-profit organization, reported that new thyroid cancer cases were projected to reach 44,020 in 2025, up from 43,720 in 2023. Thus, the growing number of thyroid cancer cases is fueling the expansion of the hypoparathyroidism market.

Leading companies in the hypoparathyroidism market are concentrating on developing technologically advanced products, such as those based on TransCon technology, to enhance treatment effectiveness and improve patient outcomes. TransCon (Transient Conjugation) technology is a proprietary platform designed to optimize drug delivery. For example, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched YORVIPATH (palopegteriparatide), its second product utilizing TransCon technology, in Germany and Austria for treating adults with chronic hypoparathyroidism. YORVIPATH is a once-daily prodrug of parathyroid hormone (PTH 1-34) engineered to maintain physiological PTH levels over 24 hours, effectively addressing the hormone deficiency underlying chronic hypoparathyroidism.

In July 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Amolyt Pharma SAS for an undisclosed sum. Through this acquisition, AstraZeneca intends to bolster its rare disease portfolio, especially within endocrine disorders, by leveraging Amolyt Pharma’s innovative pipeline and clinical-stage therapies. Amolyt Pharma SAS, based in France, is a biotechnology firm developing eneboparatide, a long-acting parathyroid hormone analog for hypoparathyroidism treatment.

Major players in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.

North America was the largest region in the hypoparathyroidism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoparathyroidism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypoparathyroidism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH) by the parathyroid glands, resulting in low calcium and high phosphorus levels in the blood. The main role of parathyroid hormone (PTH) is to regulate and maintain stable calcium and phosphorus levels, which are vital for nerve, muscle, and bone function. Hypoparathyroidism may occur due to surgical removal or damage to the parathyroid glands, autoimmune diseases, genetic disorders, or, in rare cases, unknown causes.

The primary treatments for hypoparathyroidism include hormone replacement therapy and adjunctive therapies. Hormone replacement therapy (HRT) involves administering hormones to replace or supplement those that the body no longer produces adequately. Treatment options include hormone replacement therapy, calcium and vitamin D supplements, and emerging therapies. These treatments are administered through oral or parenteral routes and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, serving various end users such as hospitals, specialty clinics, and homecare settings.

The hypoparathyroidism market research report is one of a series of new reports that provides hypoparathyroidism market statistics, including hypoparathyroidism industry global market size, regional shares, competitors with hypoparathyroidism market share, hypoparathyroidism market segments, market trends and opportunities, and any further data you may need to thrive in the hypoparathyroidism industry. This hypoparathyroidism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypoparathyroidism market consists of revenues earned by entities by providing services such as diagnostic testing, patient monitoring, telemedicine consultations, and specialized care for chronic disease management and education. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoparathyroidism market also includes sales of phosphate binders, and medical devices or diagnostic kits used for monitoring calcium, phosphorus, and parathyroid Hormone levels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.